- 251 Downloads
In the EU, the approved use of erlotinib (Tarceva®), an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has recently been expanded to include first-line treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC) in patients with EGFR-activating mutations. In randomized, open-label, phase III clinical trials, oral erlotinib reduced the risk of progression, improved response rates, and was well tolerated relative to standard platinum-based doublet chemotherapy in Caucasian and Asian populations with advanced NSCLC with EGFR-activating mutations.
KeywordsEpidermal Growth Factor Receptor Gefitinib Erlotinib National Comprehensive Cancer Network Epidermal Growth Factor Receptor Mutation
The preparation of this article was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from comments received were by the author on the basis of scientific and editorial merit.
- 7.National Comprehensive Cancer Network. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology (NCCN guidelines®): non-small cell lung cancer. Version 3.2012. Fort Washington: National Comprehensive Cancer Network; 2012.Google Scholar
- 9.Tarceva (erlotinib) film-coated tablets: summary of product characteristics. London: European Medicines Agency; 2012.Google Scholar
- 12.Ling YH, Li T, Yuan Z, et al. Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines. Mol Pharmacol. 2007;72(2):248–58.PubMedCrossRefGoogle Scholar
- 13.Ling YH, Lin R, Perez-Soler R. Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptor L858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK. Mol Pharmacol. 2008;74(3):793–806.PubMedCrossRefGoogle Scholar
- 16.Jackman DM, Miller VA, Cioffredi LA, et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res. 2009;15(16):5267–73.PubMedCrossRefGoogle Scholar
- 17.Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–46.PubMedCrossRefGoogle Scholar
- 19.Zhou C, Wu YL, Liu X, et al. Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC) [abstract no. 7520]. J Clin Oncol. 2012;30(15 Suppl):7520.Google Scholar
- 20.National Institute for Health and Clinical Excellence. Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer: NICE technology appraisal guidance 258. London: National Institute for Health and Clinical Excellence; 2012.Google Scholar